Samsung生物logics计划将其生物相似的药物单位剥离,更多地侧重于制造服务。 Samsung Biologics plans to spin off its biosimilar drug unit to focus more on manufacturing services.

Samsung生物logics计划将其生物相似的药物开发单位转变为一个名为Samsung Epis Holdings的新实体,目的是更加注重其合同开发和制造服务。 Samsung Biologics plans to spin off its biosimilar drug development unit into a new entity called Samsung Epis Holdings, aiming to focus more on its contract development and manufacturing (CDMO) services. 这一举措将在9月16日股东会议之后完成,旨在加强业务独立性和提高企业竞争力。 This move, set to be finalized after a shareholders meeting on September 16, aims to enhance operational independence and boost business competitiveness. 分成两部分处理潜在的利益冲突问题,有助于精简业务,而三星生物生物学则力求为股东争取最大的价值。 The split addresses potential conflicts of interest and helps streamline operations, with Samsung Biologics looking to maximize value for shareholders.